Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2023-09-29 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Theralase Technologies Inc. announcing the successful demonstration of an 8-year shelf life for their lead drug Ruvidar. It contains no financial statements, regulatory filings, or detailed financial data. It is a corporate announcement about product stability and clinical development plans, not a financial report or regulatory filing. The document is approximately 6,468 characters, which is relatively short and typical for a press release. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other detailed financial or regulatory document. It is also not a report publication announcement since it does not mention the release or availability of a report. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements and press releases that do not fit other categories.
2023-09-29 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the successful completion of a non-GLP preclinical toxicology analysis for a drug candidate targeting brain cancer. It discusses preclinical data, plans for future clinical studies, and forward-looking statements. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The content is primarily an update on research and development progress and clinical trial plans, typical of a Capital/Financing Update or a general corporate update. Since it is a press release about scientific and clinical progress rather than a financial or regulatory filing, the most appropriate classification is Capital/Financing Update (CAP).
2023-09-27 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the grant of stock options to certain directors and employees of Theralase Technologies Inc. It details the number of options granted, exercise price, vesting period, and expiration. There is no financial data, regulatory filing, or detailed report content. The document is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or certification. It is an announcement related to stock options, which falls under capital/financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is about 4974 characters, which is consistent with a press release rather than a full report.
2023-09-21 English
Annual information form - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Theralase® Technologies Inc. Annual Information Form Year-ended December 31, 2022' and dated September 20, 2023. It contains detailed sections typical of an Annual Information Form (AIF), including corporate structure, business summary, risk factors, capital structure, directors and officers, legal proceedings, and other comprehensive corporate disclosures. The AIF is a regulatory filing commonly used in Canadian securities regulation to provide detailed information about a company, similar but distinct from an annual report (10-K). The document is lengthy (15,000 characters) and contains substantive information rather than just an announcement or certification. Given the nature and content, this document fits best under the category of Regulatory Filings (RNS), as the AIF is a regulatory disclosure document that does not fit the other more specific categories like Annual Report (10-K) or Management Reports (MDA).
2023-09-20 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the resignation of a board member, Antoine Leboyer, from Martello Technologies Group Inc. It discusses the director's background, reasons for resignation, and includes quotes from company leadership. There is no financial data, no mention of financial results, no regulatory filings, or report attachments. The content focuses solely on a change in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 6999 characters, which is sufficient for a detailed announcement but does not contain financial or regulatory report content.
2023-09-08 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2023-08-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.